Background. Metabolic profiling may provide insight into biologic mechanisms related to the maintenance of muscle and fat-free mass in functionally limited older adults. The objectives of the study were to characterize the association between thigh muscle cross-sectional area (CSA) and the fat-free mass index (FFMI; total lean mass/height 2 ) with the serum metabolite profile, to further identify significant metabolites as associated with markers of insulin resistance or inflammation, and to develop a metabolite predictor set representative of muscle CSA and the FFMI in functionally limited older adults.
S kELETAL muscle mass, representing the largest fraction of total body fat-free mass (1) , has been reported to decline at a rate of 1%-2% per year in persons older than 50 years (2) , resulting in reduced strength and functional capacity (3) . Therefore, identification of mechanisms related to the maintenance of muscle and fat-free mass in older adults may be important for addressing the growing challenge that health care will face with physical disablement in the expanding aging population.
The presence of insulin resistance or inflammation may be related to the maintenance of muscle mass in older adults. Insulin-resistant older adults have been shown to lose muscle mass at a greater rate than noninsulin-resistant subjects (4) , an important finding because age-related losses in muscle mass reduce the amount of available insulin-responsive tissue, thereby promoting insulin resistance, which, in turn, may result in the further loss of muscle mass and reduced insulin sensitivity (5) . Similarly, the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) have each been shown to induce skeletal muscle protein breakdown (6, 7) and are elevated in subjects with reduced muscle mass (8) . Therefore, identification of insulin resistance or inflammation-related metabolites that are associated with muscle mass may lead to an improved understanding of mechanisms related to the maintenance of muscle mass in older adults.
One approach that can be used to identify insulin resistance or inflammation-related metabolites that are significantly associated with muscle mass in older adults is mass spectrometry-based metabolomics, which (when an untargeted approach is used) aims to characterize and quantify all of the metabolites in a biological sample, thereby providing an analytical description of complex metabolic processes (9) . Mass spectrometry-based metabolomic signatures have proven their value in several diseases, including diabetes and cardiovascular disease (10) , and, cancer (11) . Various mass spectrometry-based metabolite groups have been previously shown to be associated with insulin resistance or inflammation, including amino acids, fatty acids, acylcarnitines, and lysophosphatidylethanolamines (12) (13) (14) . Therefore, the goals of the present study were to examine the association between serum mass spectrometry metabolites (previously shown to be associated with insulin resistance or inflammation) with thigh muscle cross-sectional area (CSA) and the fat-free mass index (FFMI), to further identify significant metabolites as associated with markers of insulin resistance or inflammation, and to develop a metabolite predictor set representative of muscle CSA and the FFMI, in functionally limited older adults.
Materials and Methods

Participants
Serum from 73 older adults (age range: 70-85 years) with a demonstrated reduction in mobility (a score of 10 or less on the Short Physical Performance Battery) from the randomized, double-blind, controlled study of Chalé coworkers (2012) (15) was subjected to analysis. All participants were required to be sedentary, defined as the absence of structured exercise during the previous 6 months. The study protocol was approved by the Tufts University Health Sciences Campus Institutional Review Board.
Measurement of Muscle CSA by Computed Tomography
Following an 8-hour fast, muscle CSA, defined as the sum of normal density (35-100 Hounsfield units) plus lowdensity muscle (0-34 Hounsfield units), was measured by computed tomography on the nondominant thigh at the midpoint of the femur using a Siemens Somotom Scanner (Erlangen, Germany). Scans were analyzed by a technician in a blinded manner using SliceOmatic v4.2 software (Montreal, Canada), as described previously (16) .
Measurement of Fat-Free Mass by Dual-Energy x-Ray Absorptiometry
Whole-body dual-energy x-ray absorptiometry scans were performed using a Hologic Discovery A densitometer and were analyzed using Hologic QDR software version 12.3 in array mode (Hologic, Inc. Bedford, MA). Scan acquisition and analysis were performed according to manufacturer guidelines, with three passes over the subject to acquire the full dual-energy x-ray absorptiometry image. Total body measurement of fat-free mass was reported. To account for intersubject differences in height, fat-free mass was divided by height 2 to obtain the FFMI.
Metabolomic Analysis
Ten milliliters of blood was collected under standardized conditions between 8 and 10 am and following an overnight fast. After collection, blood was allowed to clot for 1 hour at room temperature and was centrifuged at 2,135g for 10 minutes at 4°C. Serum was derived by removing the supernatant following centrifugation and was stored in 1 mL aliquots at −80°C, prior to analysis.
Metabolomic data acquisition was performed by Metabolon Inc. (Research Triangle Park, NC). Briefly, small molecule metabolites were extracted from serum, and the reconstituted extracts were resolved using mass spectrometry platforms, including ultrahigh performance liquid chromatography/tandem mass spectrometry optimized for acidic and basic species and gas chromatography/mass spectrometry, with details of this platform described extensively by Evans coworkers (2009) (17) and as reported by Lustgarten coworkers (2012) (18) . Of the 296 metabolites that were identified, 182 metabolites were determined to be representative of fatty acids, amino acids, acylcarnitines, and lysophosphatidylethanolamines (12) (13) (14) and, therefore, were used in multivariable statistical analyses. Metabolites that were not included for analysis included purines, pyrimidines, bile acids, steroids, benzoates, hemoglobin, and fibrinogen cleavage peptides.
Measurement of Homeostasis Model Assessment of Insulin Resistance, TNF-α, and IL-6
Serum glucose was measured by the hexokinase method using a Beckman-Coulter AU400e chemistry system (Beckman-Coulter, Diagnostic Division, Brea, CA). Serum insulin was measured using a competitive binding radioimmunoassay (HI-14k Human Insulin Specific kit; Millipore, St. Charles, MO). The homeostasis model assessment of insulin resistance (HOMA-IR) is commonly used in large epidemiological studies and in clinical practice to estimate insulin resistance from fasting plasma insulin and glucose concentrations (19) . HOMA-IR was calculated with the following formula: (fasting serum insulin [mU/L] × fasting plasma glucose [mmol/L])/22.5 (19) .
Quantikine high sensitivity ELISA kits (R&D Systems, Stillwater, MN) were used to measure serum levels of TNF-α and IL-6, as recommended by the manufacturer.
Determination of Average Daily Protein Intake
Average daily protein intake was determined based on selfreported food intake using a 3-day diet record (15) . Dietary intake data were analyzed using Nutrition Data System for Research software version 2007 (Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN).
Statistics
Linear regression (SAS Enterprise Guide 4.3; SAS Institute Inc., Cary, NC) was used in multivariable analyses to determine the association between individual metabolites with muscle CSA and FFMI, to determine if significant metabolites were also associated with markers of insulin resistance or inflammation, and to identify a metabolite predictor set representative of muscle CSA or the FFMI.
Separate multivariable linear regression models were performed for each mass spectrometry-based metabolite. Muscle CSA and FFMI models included sex, age, total fat (because participants with elevated muscle or lean mass may have elevated fat mass), and metabolite. HOMA-IR, TNF-α, and IL-6 models included sex, age, and metabolites found to be significantly associated with muscle CSA or the FFMI. Metabolite parameter estimates are based on a 1-unit increase in the median scaled, natural log transformed metabolite data. False discovery rates (20) were computed with use of the q value method (21) to adjust for multiple comparisons. Statistical significance for mass spectrometry metabolites was set at p ≤ .05 and q ≤ .30 (22) .
To determine a metabolite predictor set representative of muscle CSA or the FFMI, sex-, age-, and total fat-adjusted stepwise linear regression was used on metabolites that were found to be significantly associated with muscle CSA or the FFMI. When stepwise selection is used, metabolites enter and remain in the model only if they are statistically significant (p ≤ .05) after inclusion. Internal validation of the stepwise linear regression models was performed using a bootstrap resampling procedure of the data set, using 200 individual bootstrap replicates. The prespecified models were fitted to each, and an empiric 95% confidence interval (95% CI) was generated about the median of the 200 replicate parameter estimate values for each covariate.
Results
General physical characteristics for all participants, including age, percentage of females, average daily protein intake, body weight, body mass index, muscle CSA, FFMI, insulin, glucose, HOMA-IR, TNF-α, and IL-6 are shown in Table 1 .
Metabolites Associated With Muscle CSA or the FFMI
Significant associations between 20 metabolites with thigh muscle CSA were identified, including positive associations for nine branched chain amino acids (BCAAs) and BCAA-related metabolites (leucine, isoleucine, 3-methyl-2-oxovalerate, valine, 4-methyl-2-oxopentanoate, α-hydroxyisocaproate, 3-methyl-2-oxobutyrate, 3-hydroxyisobutyrate, and 3-hydroxy-2-ethylpropionate) and two carnitines (isovalerylcarnitine and deoxycarnitine).
Negative associations were found for one BCAA-related metabolite (2-hydroxyisobutyrate), for four amino acid metabolites (C-glycosyltryptophan, N-acetylserine, N-acetylornithine, and indolepropionate), for two carnitines (methylglutarylcarnitine and tiglyl carnitine), and for two lysophospholipids (1-linoleoylglycerophosphoethanolamine and 2-linoleoylglycerophosphoethanolamine). No significant associations between fatty acids with muscle CSA were identified ( Table 2) . Two of the 20 metabolites (2-hydroxyisobutyrate and deoxycarnitine) that were found to be significantly associated with muscle CSA were no longer statistically significant after further adjustment for average daily dietary protein intake (data not shown).
Significant associations between 16 metabolites with the FFMI were identified, including positive associations for eight BCAAs and BCAA-related metabolites (leucine, isoleucine, valine, 3-hydroxyisobutyrate, 2-hydroxy-3-methylvalerate, 4-methyl-2-oxopentanoate, 3-methyl-2-oxovalerate, and α-hydroxyisocaproate), for two amino acid metabolites (imidazole propionate and β-alanine), and two carnitines (isovalerylcarnitine and propionylcarnitine). Negative associations were found for three fatty acid metabolites (octadecanedioate, tetradecanedioate and hexadecanedioate) and for one amino acid metabolite (indolepropionate). No significant associations between lysophosphatidylethanolamines with the FFMI were identified (Table 3) . Statistical significance for all 16 significant metabolites remained after further adjustment for average daily dietary protein intake (data not shown).
Nine metabolites, including seven BCAAs or BCAA-related metabolites (leucine, isoleucine, valine, 3-hydroxyisobutyrate, 4-methyl-2-oxopentanoate, 3-methyl-2-oxovalerate, and α-hydroxyisocaproate), one tryptophanrelated metabolite (indolepropionate), and one carnitine (isovalerylcarnitine), were found to be significantly associated with both muscle CSA and the FFMI. 96.0 ± 11.6 HOMA-IR 3.7 ± 2.0 TNF-α (pg/mL) 1.4 ± 0.9 IL-6 (pg/mL) 2.3 ± 1.4
Notes: Values shown represent means ± SD. BMI = body mass index; CSA = cross-sectional area; FFMI = fat-free mass index; HOMA-IR = homeostasis model assessment of insulin resistance; IL-6 = interleukin-6; TNF-α = tumor necrosis factor-α.
Metabolites Associated With Muscle CSA or the FFMI and HOMA-IR, TNF-α, or IL-6
To determine if metabolites that were found to be significantly associated with muscle CSA or the FFMI were associated with markers of insulin resistance or inflammation, we then analyzed the association between significant metabolites with sex-and age-adjusted HOMA-IR, TNF-α, or IL-6. None of the metabolites that were significantly associated with muscle CSA were found to be associated with HOMA-IR. In contrast, two metabolites that were found to be positively associated with the FFMI (propionylcarnitine and 2-hydroxy-3-methylvalerate) were found to be positively associated with HOMA-IR (Table 4) .
In terms of the association between significant metabolites with markers of inflammation, 3-hydroxy-2-ethylpropionate was found to be positively associated with muscle CSA and negatively associated with TNF-α. β-Alanine was found to be positively associated with both the FFMI and IL-6. Indolepropionate was found to be negatively associated with both the FFMI and muscle CSA but was found to be positively associated with IL-6. Similarly, C-glycosyltryptophan was found to be negatively associated with muscle CSA but was found to be positively associated with both TNF-α and IL-6 (Table 4) .
Stepwise Regression Identifies Metabolite Predictors of Muscle CSA and the FFMI
To determine overall predictors of muscle CSA and the FFMI, sex-, age-, and total fat-adjusted stepwise regression was performed in separate models. Although sex, age, and total fat were found to explain 47.4% of the variability inherent in muscle CSA, a combination of four metabolites, including BCAAs and BCAA-related metabolites (leucine and α-hydroxyisocaproate) and tryptophan-related, inflammation-associated markers (C-glycosyltryptophan and indolepropionate) were found to explain an additional 21.0%, for a total adjusted R 2 of 68.4% (Table 5) . Similarly, although sex, age, and total fat were found to explain 42.7% of the variability inherent in the FFMI, a combination of three metabolites, including leucine, indolepropionate, and a fatty acid metabolite (octadecanedioate), were found to explain an additional 24.9%, for a total adjusted R 2 of Notes: All models were adjusted for sex, age, and total fat. Metabolites are listed with their respective parameter estimates and standard errors (β ± SE) in order of significance (p value) and with q values. FFMI = fat-free mass index. Notes: All models were adjusted for sex, age, and total fat. Metabolites are listed with their respective parameter estimates and standard errors (β ± SE) in order of significance (p value) and with q values. CSA = cross-sectional area.
67.6% (Table 5 ). To assess internal validity of the results obtained from stepwise regression, bootstrapping was performed. Two hundred bootstrap samples were created, and the variables that were found to be significant in the stepwise model were forced in. The median R 2 across the bootstrap replicates for the muscle CSA and FFMI models was found to be .72 (95% CI: 0.62, 0.81) and .70 (95% CI: 0.59, 0.82), respectively, which is similar to the model performance found in the stepwise models (Table 5 ).
Discussion
The goals of the current study were to identify serum metabolites containing significant associations with thigh muscle CSA and the FFMI, to examine the association between significant metabolites with markers of insulin resistance and inflammation, and to identify a metabolite predictor set representative of thigh muscle CSA and the FFMI in functionally limited older adults. Twenty and 16 metabolites were found to be significantly associated with thigh muscle CSA and the FFMI, respectively. Seven BCAAs and BCAA-related metabolites were found to be significantly associated with both muscle CSA and the FFMI, thereby suggesting BCAAs and BCAA-related metabolites as potential markers of muscle and fat-free mass. Six metabolites, including BCAA-related and tryptophan metabolic products, were identified as insulin resistance or inflammation-associated markers of either muscle CSA or the FFMI. Finally, multivariable-adjusted metabolite predictor sets that included BCAAs and tryptophan metabolic products were found to explain approximately 68% of the variability inherent in muscle CSA and the FFMI, respectively. Collectively, these data strengthen the case for BCAAs as markers of muscle and fat-free mass and suggest novel BCAA-related and tryptophan metabolic products as insulin resistance or inflammation-associated markers of muscle CSA or the FFMI in functionally limited older adults.
The BCAAs-leucine, isoleucine, and valine-have been previously reported to be positively associated with the FFMI in older adults (average age: 63 years) (23) . Our findings extend these results to functionally limited older adults (average age: 78 years), as we found significant positive associations between leucine, isoleucine, and valine with both muscle CSA (a more specific measure of muscle mass than fat-free mass) and the FFMI. To explain these associations, it has been postulated that during overnight fasting, serum BCAA concentrations are increased in proportion to the muscle mass of the body (24) . In addition, leucine and its related metabolic products have been shown to stimulate protein synthesis (25) , to reduce protein degradation (4-methyl-2-oxopentanoate) (26) , and to increase lean mass (α-hydroxyisocaproate) (27) . The novel positive associations found between four additional BCAA-related metabolites with both muscle CSA and the FFMI provide further evidence of BCAAs and BCAA-related metabolites as serum markers of muscle and the FFMI in functionally limited older adults.
Circulating BCAAs may also be indicative of insulin resistance, as they have been shown to be positively associated with HOMA-IR in children (age range: 8-13 years) (28) , with the future development of insulin resistance in young adults (average age: 32 years) (29) , and with HOMA-IR in middleaged adults (average age: 51 years) (13) . It is important to note that in the current study, we found a significant positive association between HOMA-IR with the FFMI (but not with muscle CSA; β ± SE, 0.4 ± 0.1, p = .005). Furthermore, based on measurements in individuals studied with the euglycemic-insulin clamp technique, Stern coworkers (2005) (30) determined that a diagnosis of insulin resistance should be made in subjects if any of the following conditions were met: body mass index >28.9 kg/m 2 , HOMA-IR >4.65 or body mass index >27.5 kg/m 2 and HOMA-IR >3.60. Using these criteria, 28 of the 73 participants in the current study were found to be insulin resistant. Therefore, it is possible that the positive associations found for BCAAs with muscle CSA or the FFMI are not only indicative of elevated muscle mass but also of insulin resistance. To explore this possibility, we investigated whether metabolites that were found to be associated with either thigh muscle CSA or the FFMI were also associated with HOMA-IR, and we identified one BCAArelated metabolite (2-hydroxy-3-methylvalerate) and one carnitine (propionylcarnitine) to be significantly associated with both HOMA-IR and the FFMI. 2-Hydroxy-3-methylvalerate is a metabolic product of isoleucine (31) . Elevated levels of 2-hydroxy-3-methylvalerate stimulate lipid peroxidation in homogenates of rat brain (32) , a finding that may explain the elevated levels of lipid peroxidation found in insulin-resistant subjects (33) . Separately, propionylcarnitine has been previously been shown to be associated with the FFMI (23) and to be elevated in insulin-resistant subjects (13, 34) . However, because the majority of BCAAs and BCAA-related metabolites were not found to be associated with HOMA-IR, our results suggest BCAAs as markers of muscle and fat-free mass, but not of insulin resistance (with the exception of 2-hydroxy-3-methylvalerate), in functionally limited older adults.
Four metabolites were identified as inflammationassociated markers of muscle CSA or the FFMI, including 3-hydroxy-2-ethylpropionate, indolepropionate, C-glycosyltryptophan, and β-alanine. It is interesting to note that although the isoleucine degradation products, 2-hydroxy-3-methylvalerate and 3-hydroxy-2-ethylpropionate (31), were found to be positively associated with the FFMI and muscle CSA, respectively, 2-hydroxy-3-methylvalerate was found to be positively associated with HOMA-IR, whereas 3-hydroxy-2-ethylpropionate was found to be negatively associated with TNF-α. These data illustrate the differing involvement of isoleucine degradation products on markers of insulin resistance and inflammation in functionally limited older adults. Separately, two tryptophan-related metabolites, indolepropionate and C-glycosyltryptophan, and, β-alanine and were found to be associated with inflammatory markers and, with muscle CSA or the FFMI. Indolepropionate is produced by the degradation of tryptophan by gut bacteria (35, 36) , a novel finding that associates a product of gut microbial metabolism with baseline levels of both muscle and fat-free mass. Interestingly, other tryptophan degradation products, including 3-indoxyl sulfate, indoleacetate, and kynurenine, were found to be positively associated with either TNF-α or IL-6 but not with muscle CSA or the FFMI in the current study (data not shown). The production of kynurenine from tryptophan is well documented to be stimulated by proinflammatory cytokines (37) . Although indolepropionate has been shown to act as an antioxidant (38) , our findings suggest that indolepropionate and other tryptophan-related metabolic products are associated with proinflammatory pathways that may have negative consequences on the maintenance of muscle mass in functionally limited older adults. In addition, the novel association found for C-glycosyltryptophan with both IL-6 and TNF-α and with muscle CSA further illustrates the role of inflammation-associated, tryptophan-related metabolites on reduced levels of muscle mass in older adults. Separately, β-alanine (aminopropionate) is an amine derivative of propionic acid, a three-carbon fatty acid that has been shown to be elevated as a result of BCAA catabolism in insulin-resistant subjects (13, 34) . However, we did not find an association between β-alanine with HOMA-IR in the current study. In contrast, we report for the first time, β-alanine as a marker of both inflammation and the FFMI.
Use of stepwise regression identified the combination of BCAA-related (leucine and α-hydroxyisocaproate) and tryptophan-related metabolic products (C-glycosyltryptophan and indolepropionate) as a metabolite predictor set representative of muscle CSA. Similarly, leucine and indolepropionate were found in the final stepwise model for the FFMI, thereby strengthening the potential importance of these metabolites as markers of muscle and fatfree mass in functionally limited older adults. In contrast with the results found for stepwise regression for muscle CSA, octadecanedioate was found in the final stepwise FFMI model. Octadecanedioate (C18) is a saturated dicarboxylic fatty acid, which is thought to be derived from long-chain fatty acids by peroxisomal β-oxidation when mitochondrial β-oxidation is severely impaired (39) . Interestingly, although tetradecanoate and hexadecanoate did not enter the final stepwise model, these three saturated dicarboxylic acids-octadecanedioate, tetradecanoate, and hexadecanoate-were found to be significantly negatively associated with the FFMI. Incubation of mitochondria with hexadecanoate (C16) and the amount of C16 and C18 dicarboxylic acids found in serum has been shown to be associated with reduced mitochondrial adenosine triphosphate production (40) . Therefore, these data suggest that participants with a reduced FFMI may have both reduced lean mass and defective mitochondrial energy production.
Study Limitations
There are several limitations of the results found in the current study. First, because of our cross-sectional design, whether these metabolites are important insulin resistance or inflammation-associated markers of time-dependent changes in muscle area is unknown. Future studies designed to examine longitudinal associations between these metabolites with insulin resistance, inflammation, and muscle mass are of interest. Second, although HOMA-IR is a clinically validated measure of insulin resistance, the gold standard of diagnosing insulin resistance is use of the euglycemicinsulin clamp technique. Therefore, improved analytical accuracy may be obtained by identifying metabolite markers representative of insulin resistance with use of the euglycemic-insulin clamp technique. Third, although we identified metabolites associated with markers of systemic inflammation and either muscle CSA or the FFMI, the association between muscle-produced inflammation with serum metabolites is unknown. Future studies designed to examine the association between muscle-produced inflammation with the serum metabolite profile are of interest.
Conclusions
The BCAAs-leucine, isoleucine, and valine-have been previously reported to be associated with the FFMI in older adults (average age: 63 years). Results obtained in the current study extend these findings to functionally limited older adults (average age: 78 years), as the BCAAs, leucine, isoleucine, and valine (and four additional BCAA-related metabolites), were found to be significantly associated with both thigh muscle CSA and the FFMI. Because BCAAs have also been reported as markers of insulin resistance, we then sought to determine if metabolites significantly associated with muscle CSA or the FFMI were associated with HOMA-IR and found the BCAA metabolites-2-hydroxy-3-methylvalerate and propionylcarnitine-as HOMA-IRassociated markers of the FFMI. Furthermore, we identified novel associations for one BCAA metabolite, two tryptophan-related metabolites, and β-alanine with markers of inflammation and with muscle CSA or the FFMI. Finally, use of multivariable-adjusted stepwise regression identified combinations of metabolites that were able to explain approximately 68% of the variability inherent in muscle CSA or the FFMI. Collectively, these data indicate BCAAs and BCAA-related metabolites as serum markers of muscle and fat-free mass. In addition, further analysis identified novel insulin resistance or inflammation-associated markers of muscle and fat-free mass in functionally limited older adults. Future studies designed to validate these results in a separate, larger cohort are of interest. 
